The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
We propose a Bayesian optimal phase II (BOP2) design for clinical trials with a time‐to‐event endpoint (eg, progression‐free survival [PFS]) or co‐primary endpoints consisted of a time‐to‐event endpoint and a categorical endpoint (eg, PFS and toxicity). We use an exponential‐inverse gamma model to model the time to event. At each interim, the go/no‐go decision is made by comparing the posterior probabilities...
For oncology drug development, phase II proof‐of‐concept studies have played a key role in determining whether or not to advance to a confirmatory phase III trial. With the increasing number of immunotherapies, efficient design strategies are crucial in moving successful drugs quickly to market. Our research examines drug development decision making under the framework of maximizing resource investment,...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.